The effect of TEAS on the quality of early recovery in patients undergoing gynecological laparoscopic surgery: a prospective, randomized, placebo-controlled trial

摘要

INTRODUCTION:In current study we assessed the effect of transcutaneous electrical acupoint stimulation (TEAS) on the quality of early recovery in patients undergoing gynecological laparoscopic surgery.METHODS:Sixty patients undergoing gynecological laparoscopic surgery were randomly assigned to TEAS (TEAS group) or control group (Con group). TEAS consisted of 30?min of stimulation (12-15?mA, 2/100?Hz) at the acupoints of Baihui (GV20), Yingtang (EX-HN-3), Zusanli (ST36) and Neiguan (PC6) before anesthesia. The patients in the Con group had the electrodes applied, but received no stimulation. Quality of recovery was assessed using a 40-item questionnaire as a measure of quality of recovery (QoR-40; maximum score 200) scoring system performed on preoperative day 1 (T0), postoperative day 1 (T1) and postoperative day 2 (T2); 100-mm visual analogue scale (VAS) scores at rest, mini-mental state examination (MMSE) scores, the incidence of nausea and vomiting, postoperative pain medications, and antiemetics were also recorded.RESULTS:QoR-40 and MMSE scores of T0 showed no difference between two groups (QoR-40: 197.50?±?2.57 vs. 195.83?±?5.17), (MMSE: 26.83?±?2.74 vs. 27.53?±?2.88). Compared with the Con group, QoR-40 and MMSE scores of T1 and T2 were higher in the TEAS group (P??0.05) (QoR-40: T1, 166.07?±?8.44 vs. 175.33?±?9.66; T2, 187.73?±?5.47 vs. 191.40?±?5.74), (MMSE: T1, 24.60?±?2.35 vs. 26.10?±?2.78; T2, 26.53?±?2.94 vs. 27.83?±?2.73). VAS scores of T1 and T2 were lower (P??0.05) in the TEAS group (T1, 4.73?±?1.53 vs. 3.70?±?1.41; T2, 2.30?±?0.95 vs. 1.83?±?0.88); the incidence of postoperative nausea and vomiting (PONV), remedial antiemetics and remedial analgesia was lower in the TEAS group (P??0.05) (PONV: 56.7% vs. 23.3%; incidence of remedial antiemetics: 53.3% vs. 23.3%; incidence of remedial analgesia: 80% vs. 43.3%).CONCLUSION:The use of TEAS significantly promoted the quality of early recovery, improved MMSE scores and reduced the incidence of pain, nausea and vomiting in patients undergoing gynecological laparoscopic surgery.TRIAL REGISTRATION:ClinicalTrials.gov, NCT02619578. Registered on 2 December 2015. Trial registry name: https://clinicaltrials.gov.